Latest news with #LupinLtd
Time of India
20-05-2025
- Business
- Time of India
Lupin partners with Honeywell for usage of propellant for inhalers
Lupin Ltd partners with Honeywell to incorporate 'Solstice Air' propellant in next-generation inhalers for asthma and COPD, aiming to reduce carbon emissions. This collaboration makes Lupin the first Indian pharma company to use Solstice Air at scale in pressurized metered-dose inhalers (pMDIs). Solstice Air offers a sustainable alternative, reducing greenhouse gas emissions by up to 99.9%. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Pharma major Lupin Ltd on Tuesday said it has partnered with Honeywell to use the latter's propellant ' Solstice Air ' to transform respiratory care through the development of next-generation inhalers . Designed for patients with asthma and chronic obstructive pulmonary disease ( COPD ), Honeywell 's 'Solstice Air' has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions, the company said in a statement. Lupin 's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact ," Lupin CEO Vinita Gupta Energy and Sustainability Solutions Business President Jeff Dormo said,"Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions ."Lupin said it intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurised metered-dose inhalers (pMDIs).Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9 per cent, it added."By investigating the use of this innovative, nonflammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD," the company terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin, it added.
Time of India
13-05-2025
- Business
- Time of India
Lupin launches generic version of kidney disorder treatment drug in US
Pharma major Lupin Ltd on Tuesday said it has launched the generic version of Tolvaptan tablets used to slow kidney function decline in the US market , following the recent approval received from the country's health regulator. The company has launched Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg in the US, after receiving the approval from the US Food and Drug Administration ( USFDA ). #Operation Sindoor The damage done at Pak bases as India strikes to avenge Pahalgam Why Pakistan pleaded to end hostilities Kashmir's Pahalgam sparks Karachi's nightmare "Lupin holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity," Lupin said in a statement. Tolvaptan tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company, Ltd, and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), it added. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like She is Revealing Her Secret Strategy in Commodity Trading TradeWise Learn More Undo by Taboola by Taboola Lupin CEO Vinita Gupta said the launch of Tolvaptan Tablets in the US will provide ADPKD patients with increased access to high-quality treatment options.
Business Standard
12-05-2025
- Business
- Business Standard
Sun Pharmaceutical Industries Ltd Slips 5.32%
Sun Pharmaceutical Industries Ltd has lost 2.1% over last one month compared to 1.89% gain in BSE Healthcare index and 8.08% rise in the SENSEX Sun Pharmaceutical Industries Ltd fell 5.32% today to trade at Rs 1652.1. The BSE Healthcare index is down 0.15% to quote at 41162.29. The index is up 1.89 % over last one month. Among the other constituents of the index, Suven Pharmaceuticals Ltd decreased 2.05% and Lupin Ltd lost 1.8% on the day. The BSE Healthcare index went up 18.64 % over last one year compared to the 11.79% surge in benchmark SENSEX. Sun Pharmaceutical Industries Ltd has lost 2.1% over last one month compared to 1.89% gain in BSE Healthcare index and 8.08% rise in the SENSEX. On the BSE, 37794 shares were traded in the counter so far compared with average daily volumes of 37750 shares in the past one month. The stock hit a record high of Rs 1960.2 on 30 Sep 2024. The stock hit a 52-week low of Rs 1376.75 on 04 Jun 2024.
Business Standard
06-05-2025
- Business
- Business Standard
Aurobindo Pharma Ltd Slips 3.92%, BSE Healthcare index Shed 1.06%
Aurobindo Pharma Ltd has added 8.07% over last one month compared to 3.45% gain in BSE Healthcare index and 7.28% rise in the SENSEX Aurobindo Pharma Ltd fell 3.92% today to trade at Rs 1194. The BSE Healthcare index is down 1.06% to quote at 41928.48. The index is up 3.45 % over last one month. Among the other constituents of the index, Lupin Ltd decreased 3.13% and Cipla Ltd lost 2.64% on the day. The BSE Healthcare index went up 17.28 % over last one year compared to the 9.41% surge in benchmark SENSEX. Aurobindo Pharma Ltd has added 8.07% over last one month compared to 3.45% gain in BSE Healthcare index and 7.28% rise in the SENSEX. On the BSE, 5911 shares were traded in the counter so far compared with average daily volumes of 53449 shares in the past one month. The stock hit a record high of Rs 1592.55 on 13 Sep 2024. The stock hit a 52-week low of Rs 994.35 on 07 Apr 2025.
&w=3840&q=100)
Business Standard
24-04-2025
- Business
- Business Standard
Lupin gets USFDA nod for generic kidney disease treatment drug Tolvaptan
Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of Tolvaptan tablets indicated for a certain type of kidney disease. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, Lupin said in a regulatory filing. These are bioequivalent to Jynarque tablets in the same strengths of Otsuka Pharmaceutical Company Ltd, it added. "Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Nagpur facility and will be launched soon," the company said. Commenting on the approval, Lupin CEO Vinita Gupta said,"This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally." Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), it said. These tablets had an estimated annual sale of $1,467 million in the US in 2024.
